Becton, Dickinson and CompanyNYSE: BDX
Health Care · Health Care Equipment
$149.57
+0.36%
Vol: 1.6M
Research Digest
Friday, May 1, 2026
BD declared $1.05 quarterly dividend with record employee well-being recognition, but faces recent share price declines despite undervaluation metrics.
Becton Dickinson announced a quarterly dividend of $1.05 per share ($4.20 annualized), payable June 30, 2026. The company achieved CE Marking for its Revello Vascular Covered Stent and launched a central venous catheter device. Despite recent 2.13% share price decline, analysts rate BDX as a Buy with average 12-month target of $186, implying 19.48% upside from current levels.
Previous Market Intelligence
13 daysApr 30BD launches CentroVena One all-in-one central line system and declares $1.05 quarterly dividend payable June 30Positive▶
Becton Dickinson launched the CentroVena One™ Insertion System on April 29, 2026, the first all-in-one central venous catheter device, receiving FDA 510(k) clearance and entering the FDA Safer Technologies Program. BD declared a quarterly cash dividend of $1.05 per share, payable June 30, 2026, implying an annual rate of $4.20. The company continues expanding vascular product offerings with the Liverty TIPS stent graft and PureWick urine collection system. Analysts rate BDX 'Buy' with average 12-month price target of $186.0, a 19.48% upside.
Apr 29BD launches CentroVena One central line system, FDA 510(k) clearance on April 29Neutral▶
Becton Dickinson launched the CentroVena One Insertion System on April 29, 2026—the first all-in-one central venous catheter insertion device consolidating introducer needle, syringe, guidewire and catheter. The system received FDA 510(k) clearance and entered the FDA Safer Technologies Program. It is now commercially available in the U.S. BD declared a $1.05 quarterly dividend payable June 30. The stock has declined 4.6% over 7 days and 23.3% YTD. However, analyst consensus is "Buy" with average 12-month price target of $186.0, representing 19.48% upside from current levels.
Apr 16Becton Dickinson received CE Mark approval for Liverty TIPS Stent Graft on April 8; Q2 2026 earnings webcast scheduled for May 7.Positive▶
BD announced CE Mark approval for Liverty TIPS Stent Graft, an adjustable-diameter device for portal hypertension treatment. Safety/effectiveness data from pivotal ARCH clinical trial to be presented at Society of Interventional Radiology Annual Scientific Meeting on April 12. Company will host Q2 2026 earnings webcast on May 7. COO Rick Byrd announced retirement plans. BD completed landmark spin-off of Biosciences and Diagnostic Solutions in February 2026, entering new 'Connected Care' era.
Apr 15Becton Dickinson received CE Mark for Liverty TIPS Stent Graft on April 8, 2026, advancing portal hypertension treatment in the European Union.Positive▶
Becton Dickinson announced two significant product advances in early April 2026. On April 8, the company obtained CE Mark approval for its Liverty TIPS Stent Graft to treat portal hypertension, with pivotal ARCH trial data presented at the Society of Interventional Radiology Annual Scientific Meeting on April 12. On April 9, new clinical findings showed BD PureWick Urine Collection System improved sleep and comfort for women managing nighttime incontinence. BD will report Q2 FY2026 results on May 7, 2026.
Apr 14Becton Dickinson announced leadership transition as interventional segment president Richard Byrd plans to retire in June; Q2 2026 earnings webcast set for May 7.Mixed▶
Becton Dickinson (BDX) announced that Richard E. Byrd, executive vice president of the Interventional segment, will retire in June 2026. BD plans to appoint a successor before then. Q2 FY2026 earnings discussion is scheduled for May 7, 2026. The company launched new connected care products including HemoSphere Stream Module for blood pressure monitoring. BD faces a challenging outlook with anticipated 12% revenue decline next year following the February 2026 spin-off of Biosciences and Diagnostic Solutions segments.
Apr 13CEO guidance cut, 12% revenue decline projected next year; stock down 20.4% YTD amid Alaris device challenges.Negative▶
Becton Dickinson faces significant headwinds with projected 12% revenue decline next year and stock down 20.4% year-to-date. The company reported guidance cut due to Alaris infusion device issues, creating investor capitulation. Recent developments include CE Marking for Revello Vascular Covered Stent and FDA clearance for Surgiphor wound irrigation. Despite challenges, analyst consensus rates BDX as Buy with average 12-month target of $188.73 (21.6% upside).
Apr 10BD launches new blood pressure monitoring innovation and announces executive retirement.Mixed▶
Becton Dickinson announced the launch of HemoSphere Stream Module for continuous noninvasive blood pressure monitoring on April 7. The company also announced CE Mark application for Liverty TIPS Stent Graft on April 8, and EVP Richard Byrd announced retirement after 25 years on April 9. BDX faces headwinds with projected 12% revenue decline next year and 20.4% YTD stock decline, but 12 analysts average a Buy rating with $188.73 price target.
Apr 9Becton Dickinson launches AI medication dispensing system in Europe; guidance concerns persist amid 20% YTD decline.Mixed▶
BD launched AI-enabled medication dispensing system in Europe, received CE Mark for Revello vascular stent, and FDA 510(k) clearance for Surgiphor 1000mL irrigation. Q4 EPS $2.91 beat ($2.81 est) but revenue $4.49B missed $5.15B forecast. Company faces 12% projected revenue decline next year. Stock down 20.4% YTD with recent 9.4% monthly decline. Argus cut PT to $180 from $230 (March 23). 12 analysts rate "Buy" with $188.73 PT (21.6% upside) but cautious sentiment reflects headwinds.
Apr 8Becton Dickinson launches HemoSphere Stream Module and Pyxis Pro; faces 12% revenue decline guidanceMixed▶
BD launched innovative healthcare technologies including continuous blood pressure monitoring (HemoSphere Stream Module) and AI-enabled medication dispensing in Europe (Pyxis Pro). FDA granted 510(k) clearance for breast biopsy system. Despite product innovation, company slashed full-year guidance citing renewed pressure on high-margin Alaris infusion pump division. Stock down 9.4% in past month. Analysts maintain Buy rating with 12-month target of $188.73 (21.57% upside). Earnings report scheduled for April 30, 2026.
Apr 7Q1 FY2026 earnings beat but guidance cut 15% on Alaris infusion pump pressures; stock fell 17%.Negative▶
Becton Dickinson delivered Q1 2026 EPS $2.91 and revenue $5.25B. Completed Biosciences spin-off with Waters in Feb 2026. Cut full-year EPS guidance 15% citing Alaris pricing pressure and FDA delays. FDA cleared new Surgiphor irrigation March 2. Stock fell 17% post-cut. 12 analysts rate Buy with $188.73 target.
Apr 6Becton Dickinson completes biosciences spin-off and reports Q1 2026 earnings beat.Positive▶
Becton Dickinson completed successful spin-off of BD Biosciences & Diagnostics business February 9, 2026, transforming into pure-play medical technology leader. Company delivered Q1 2026 earnings beat with $2.91 Non-GAAP EPS and $5.25B revenue, exceeding expectations. Tender offers completed with company upsizing offer caps. Pending separation positions BD for higher cash flow predictability with consumables-heavy portfolio (>90% revenue) and improved margins. Strong pipeline includes Surgiphor 1000mL irrigation system. Stock under recent pressure with 9.4% one-month decline and 11% three-month decline despite long-term strategy benefits. Analyst consensus Buy with 12-month price target of $188.73 (20.03% upside from $157.23). 12 analysts recommend Buy. P/E of 25.68, dividend yield 2.7%.
Apr 3Becton Dickinson completed February 2026 spin-off of Biosciences and Diagnostic Solutions; Q1 2026 earnings beat with $2.91 Non-GAAP EPS.Mixed▶
Becton Dickinson completed the spin-off of its Biosciences and Diagnostic Solutions business combined with Waters Corporation on February 9, 2026. Q1 2026 earnings exceeded expectations with $2.91 Non-GAAP EPS and $5.25B revenue. Launching AI-enabled medication dispensing system in Europe. Stock down 9.4% in the last month.
Apr 2Becton Dickinson beats Q1 2026 EPS at $2.91; appoints new general counselPositive▶
Becton Dickinson beats Q1 2026 EPS expectations with $2.91 Non-GAAP and $5.25B revenue; appoints Lanesha Minnix as general counsel.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| BDXBECTON | $149.57 | +0.36% | -4.0% | 11.0x | 0.35 | $42.4B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.